trending Market Intelligence /marketintelligence/en/news-insights/trending/J4YJQSwa5_vxKUqtFIXUDA2 content esgSubNav
In This List

Patent and Trademark Office OKs MediWound patent for connective tissue disease

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Patent and Trademark Office OKs MediWound patent for connective tissue disease

The U.S. Patent and Trademark Office granted a patent for MediWound Ltd.'s proprietary injectable bromelain solution, MWPC003, for the treatment of connective tissue diseases.

MWPC003 is an investigational sterile injectable solution containing a mixture of the same pharmaceutical-grade proteolytic enzymes used in the company's burn debridement treatment, Nexobrid, which is approved in Europe and other locations.

The patent provides protection for the drug in the treatment of a variety of connective tissue diseases, such as Dupuytren's contracture, Peyronie's disease and scar treatment, among others.